2 weeks ago
Hims & Hers (HIMS) Stock Soars 13% Following FDA Peptide Advisory News
Hims & Hers (HIMS) stock jumped 13% after FDA scheduled peptide review meetings. BofA raised price target to $25 amid regulatory optimism.
The post Hims & Hers (HIMS) Stock Soars 13% Following FDA Peptide Advisory News appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
Polymarket Enlists Chainalysis to Combat Insider Trading Amid US Expansion Plans
- 1 hour ago
Real-World Asset Tokenization Surpasses $30 Billion Milestone in 2026
- 1 hour ago
Real-World Asset Tokenization Surges Past $30 Billion Milestone in 2026
- 1 hour ago
Cryptocurrency Leads X Platform’s Most Silenced Topics Following Snooze Tool Rol...
- 11 hours ago
Apple (AAPL) Stock: Q2 Earnings Beat Expectations with 17% Revenue Jump and $100...